Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

This study has been terminated.
(Study closed following Phase I portion, insufficient activity to continue to Phase II.)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00354523
First received: July 18, 2006
Last updated: December 16, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2013
  Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):